Intrapleural Chemotherapy
Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716
Lung Cancer 2020 October 20 [Link] Sarah J Danson, Joe Conner, John G Edwards, Kevin G Blyth, Patricia M Fisher, Munitta Muthana, Abdulazeez Salawu, Fiona Taylor, Elizabeth Hodgkinson, Patrick Joyce, Jennifer Roman, Kathleen Simpson, Alexander Graham, Kirsty Learmonth, Penella J Woll Abstract Objectives: Malignant Pleural Mesothelioma (MPM) remains a major oncological challenge with limited therapeutic…
Read MoreCombined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
European Journal of Pharmaceutical Sciences 2018 July 17 [Link] Sonvico F, Barbieri S, Colombo P, Barocelli E, Mucchino C, Cantoni AM, Petronini PG, Rusca M, Carbognani P, Ampoll Abstract Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by a long latency period of 20-50 years after exposure to the main aetiology agent that is asbestos.…
Read MoreRadio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma
Translational Lung Cancer 2017 June [Link] Wu L, de Perrot M Abstract Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with poor outcome. Novel radical radiation techniques using intensity modulated radiation therapy (IMRT) have become an important component of therapy in mesothelioma. Immunotherapy also provides new therapeutic options. However, how best to integrate immunotherapy with…
Read MoreInduction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma
European Journal of Cardio-Thoracic Surgery 2017 May [Epub ahead of print] [Link] Casiraghi M, Maisonneuve P, Brambilla D, Solli P, Galetta D, Petrella F, Piperno G, De Marinis F, Spaggiari L Abstract OBJECTIVES: While the best approach to malignant pleural mesothelioma has yet to be demonstrated, surgery remains the mainstay of treatment. We analysed a…
Read MoreSynergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma
Oncotarget 2017 April [Epub ahead of print] [Link] Satoh T, Tatsuta T, Sugawara S, Hara A, Hosono M Abstract Malignant mesothelioma is an aggressive cancer with limited therapeutic options. Sialic acid-binding lectin isolated from Rana catesbeiana oocytes (cSBL) is a multifunctional protein with anti-cancer activity. The effects of pemetrexed, cisplatin, and cSBL were evaluated in…
Read MoreReal-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment
Photodiagnosis and photodynamic therapy 2017 February 22 [Epub ahead of print] [Link] Betrouni N, Munck C, Bensoltana W, Baert G, Dewalle-Vignion AS, Scherpereel A, Mordon S Abstract Complete and homogeneous illumination of the target is necessary for the success of a photodynamic therapy (PDT) procedure. In most applications, light dosimetry is done using detectors placed…
Read MorePharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion
Lung Cancer (Netherlands) 2017 February [Epub 2016 December 21] [Link] Sakaguchi H, Ishida H, Nitanda H, Yamazaki N, Kaneko K, Kobayashi K Abstract OBJECTIVES: Malignant pleural effusion (MPE) has a poor prognosis. Most patients are treated with tube thoracostomy and sclerotherapy, although its success rate is around 64%. We have investigated intrapleural perfusion with hyperthermic…
Read MoreIntrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model
Scientific Reports 2016 November 11 [Link] Keshava S, Rao LV, Pendurthi UR Abstract Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer with a high mortality rate as it responds poorly to standard therapeutic interventions. Our recent studies showed that expression of endothelial cell protein C receptor (EPCR) in MPM cells suppresses tumorigenicity. The present…
Read MoreIn Vitro and In Vivo Antitumor Activity of [Pt(O,O’-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma
PloS One 2016 November 2 [Link] Muscella A, Vetrugno C, Cossa LG, Antonaci G, De Nuccio F, De Pascali SA, Fanizzi FP, Marsigliante S Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy. There is an urgent need for effective therapy inasmuch as resistance, intrinsic and acquired, to conventional therapies is…
Read MoreSynergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model
International Journal of Cancer 2016 June 10 [Epub ahead of print] [Link] Kuryk L, Haavisto E, Garofalo M, Capasso C, Hirvinen M, Pesonen S, Ranki T, Vassilev L, Cerullo V. Abstract Malignant mesothelioma (MM) is a rare cancer type caused mainly by asbestos exposure. The median overall survival time of a mesothelioma cancer patient is…
Read More